Glutamine Curcumin Probiotic Composition for Depression

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current antidepressant treatments, particularly selective serotonin reuptake inhibitors (SSRIs), fail to provide remission for two-thirds of patients, and 20 to 30% of patients are resistant to all drug strategies, while psychiatric disorders like depression and anxiety have high prevalence and significant disability costs.

Innovation Solution

A synergistic combination of glutamine, turmeric extract, and Lactobacillus rhamnosus, particularly in the form of Lactobacillus rhamnosus GG, in specific proportions, effectively regulates anxiety and depressive symptoms, comparable to the reference drug clomipramine.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional antidepressant treatments (SSRIs) are used, then some patients experience symptom relief, but two-thirds of patients do not achieve remission and 20 to 30% are resistant to all drug strategies

Engineering Contradiction:

Improveefficacy of antidepressant treatmentVSAvoidresponse rate across different patient populations

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent uses a composite formulation combining three distinct active ingredients (glutamine, curcumin, and Lactobacillus rhamnosus) to create a multi-component therapeutic system. This composite approach addresses the limitations of single-molecule SSRIs by targeting multiple pathophysiological pathways simultaneously, thereby improving both reliability and adaptability across diverse patient populations with depression and anxiety disorders

Inventive Principle:

Principle #40Composite materials

Solution Approach 2:

The invention changes the fundamental parameters of antidepressant therapy by shifting from conventional SSRIs to a combination of glutamine (an amino acid precursor), curcumin (a polyphenol with anti-inflammatory properties), and Lactobacillus rhamnosus (a probiotic). This parameter change targets different mechanisms including neurotransmitter synthesis, inflammation reduction, and gut-brain axis modulation, thereby overcoming treatment resistance

Inventive Principle:

Principle #35Parameter changes

2Object-generated harmful factors

If psychiatric disorders are treated with current drug strategies, then some symptom relief is achieved, but the high prevalence (38% in Europe) and significant disability costs remain unaddressed

Engineering Contradiction:

Improvedisability and psychosocial consequencesVSAvoideffectiveness of treatment

Core Design Contradiction:

Object-generated harmful factorsVSReliability

Solution Approach 1:

The patent converts the harmful effect of chronic inflammation and oxidative stress, which are now recognized as key contributors to depression pathophysiology, into a therapeutic opportunity. Curcumin's potent anti-inflammatory and antioxidant properties, combined with glutamine's neuroprotective effects and Lactobacillus rhamnosus's ability to reduce systemic inflammation through gut-brain axis modulation, transform these harmful pathways into targets for treatment, thereby reducing disability and improving outcomes

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Data Source

PatentEP3996729B1Composition for the prevention or treatment of depression or anxiety

Publication Date: 2025.12.10 MOUSSET PIERRE YVES

Figure 1~2
Figure 3~4
Figure 5A~5C

AI summary

The present invention relates to a composition based on glutamine, extract of curcuma and Lactobacillus rhamnosus, and to the use thereof in human nutrition or for the treatment or prevention of anxiety disorders and/or mood disorders, in particular depression.